NCT01390714View on ClinicalTrials.gov

Pharmacodynamic and Pharmacokinetic Study of E3710 Following Oral Administration to Healthy, Male, Japanese Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

October 31, 2011

Study Completion Date

October 31, 2011

Conditions
Gastroesophageal Reflux Disease
Interventions
DRUG

E3710

"Arm A:~1. E3710 40 mg→RPZ 10 mg→E3710 20 mg~2. RPZ 10 mg→E3710 20 mg→E3710 40 mg~3. E3710 20 mg→E3710 40 mg→RPZ 10 mg~Crossover study of E3710 40 mg, E3710 20 mg, and PRZ 10 mg, once daily, for 5 days, oral administration."

DRUG

E3710

"Arm B:~1. E3710 40 mg→E3710 80 mg→EPZ 40 mg~2. E3710 80 mg→EPZ 40 mg →E3710 40 mg~3. EPZ 40 mg→E3710 40 mg→E3710 80 mg~Crossover study of E3710 40 mg, E3710 80 mg, and EPZ 40 mg, once daily, for 5 days, oral administration."

Trial Locations (1)

Unknown

Glendale

All Listed Sponsors
lead

Eisai Co., Ltd.

INDUSTRY

NCT01390714 - Pharmacodynamic and Pharmacokinetic Study of E3710 Following Oral Administration to Healthy, Male, Japanese Subjects | Biotech Hunter | Biotech Hunter